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Antimicrobial assesment of aroylhydrazone derivatives in vitro
Aroylhydrazones 1–13 were screened for antimicrobial and 
antibiofilm activities in vitro. N’-(2-hydroxy-phenyl methyl-
idene)-3-pyridinecarbohydrazide (2), N’-(5-chloro-2-hydro xy-
phenyl-methylidene)-3-pyridinecarbohydrazide (10), N’-(3,5-
chloro-2-hydroxyphenylmethylidene)-3-pyridinecarbohydra-
zide (11), and N’-(2-hydroxy-5-nitrophenyl methyl idene)-3-
pyridinecarbohydrazide (12) showed antibacterial activity 
against Escherichia coli, with MIC values (in µmol mL–1) of 
0.18–0.23, 0.11–0.20, 0.16–0.17 and 0.35–0.37, resp. Compounds 
11 and 12, as well as N’-(2-hydroxy-3-methoxy phenyl methyl-
idene)-3-pyridinecarbohydrazide (6) and N’-(2-hydroxy-5- 
methoxyphenylmethylidene)-3-pyridinecarbohydrazide (8) 
showed antibacterial activity against Staphylococcus aureus, 
with the lowest MIC values of 0.005–0.2, 0.05–0.12, 0.06–0.48 
and 0.17–0.99 µmol mL–1. N’-(2-hydroxy-5-methoxy phenyl-
methyl idene)-3-pyridinecarbohydrazide (7) showed antifun-
gal activity against both fluconazole resistant and susceptible 
C. albicans strains with IC90 range of 0.18–0.1 µmol mL–1. Only 
compound 11 showed activity against C. albicans ATCC 10231 
comparable to the activity of nystatin (the lowest MIC 4.0 ×10–2 
vs. 1.7 × 10–2 µmol mL–1). Good activity regarding multi-resis-
tant clinical strains was observed for compound 12 against 
MRSA strain (MIC 0.02 µmol mL–1) and compounds 2, 6 and 
12 against ESBL+ E. coli MFBF 12794, with the lowest MIC for 
compound 12 (IC50 0.16 µmol mL–1). Anti-biofilm activity was 
found for compounds 2 (MBFIC 0.015–0.02 µmol mL–1 against 
MRSA) and 12 (MBFIC 0.013 µmol mL–1 against EBSL+ E. coli). 
In the case of compound 2 against MRSA biofilm formation, 
MBFIC values were comparable to those of gentamicin sulphate, 
whereas in the case of compound 12 and EBSL+ E. coli even more 
favourable activity compared to gentamicin was observed.
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strains
Aroylhydrazones contain an azomethine group –NHN=CH– connected with carbonyl 
group, which is responsible for their different pharmaceutical applications. Therefore, 
 aroylhydrazones have attracted considerable attention for their wide range of biological 
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activities, such as antimicrobial, anticonvulsant, antitumor, analgesic, antiplatelet, antitu-
bercular and anti-inflammatory activities (1, 2). Further, hydrazones as chelating agents 
were investigated as potential drugs for the treatment of a disease called “iron overload 
disease” (3). Salicylaldehyde derivatives were shown to be selective iron chelators with 
promising pharmacological properties (4). However, pharmacokinetic studies have 
stressed the relatively short biological half-life of certain hydrazones due to hydrolysis of 
the hydrazone bond, which is typical for this class of compounds (4, 5). Molecular struc-
tural changes of aroylhydrazones derived from salicylaldehyde, o-vanilin and nicotinic 
acid hydrazide in dimethylsulphoxide/water (DMSO/water) mixtures were studied by 
NMR, UV–Vis, ATR and Raman spectroscopy (6). Results obtained by Galić et al. (6) re-
vealed that addition of water to the system did not induce tautomeric conversion of the 
ketoamino hydrazide part and the enolimino aldehyde part. Furthermore, addition of wa-
ter showed formation of hydrated molecules and compounds were quite stable in DMSO/
water mixtures (V(DMSO)/V(H2O), of 9/1, 8/2, 7/3 and 6/4 volume ratios).
According to the work done by Da Costa et al. (7), in vitro evaluated N-acylhydrazone 
derivatives of different amino acids such as l-phenylalanine, l-leucine and l-alanine 
against M. tuberculosis showed a MIC between 12.5–50 µg mL–1. In another study, done by 
Mandewale et al. (8), zinc(II) complexes with quinoline hydrazone ligands were synthe-
sized and screened for activity against M. tuberculosis (H37 RV strain) ATCC 27294. Results 
showed that two of the tested complexes were very active, with MIC value ranging from 
8.00–7.42 µmol L–1, which is comparable to the drugs ciprofloxacin (MIC value 9.41 µmol 
L–1), pyrazinamide (MIC value 25.34 µmol L–1) and streptomycin (MIC 10.74 µmol L–1) used 
to treat tuberculosis.
Benzimidazole derivatives bearing hydrazone moiety revealed that some of the com-
pounds had a bactericidal effect on the growth of Salmonella typhimurium, two times better 
or equal to the activity of chloramphenicol, which was used as a positive control (9). Ac-
tivities of these compounds against other Gram-negative bacterial strains such as Esche-
richia coli, Proteus vulgaris, Klebsiella pneumoniae or Pseudomonas aeruginosa were good, with 
the MIC value of 25–100  µg mL–1. Activities against Gram-positive bacteria were deter-
mined on four strains: Listeria monocytogenes, Staphylococcus aureus, Enterococcus faecalis and 
Bacillus subtilis. The best activity, equal to the activity of chloramphenicol, was found 
against an E. faecalis strain with the MIC value of 12.5  µg mL–1.
N
N
N
O
H
N
N
N
O
H
HO
N
N
N
O
H
HO
CH3
R
1
13
R = H (2); 3-OH (3); 4-OH (4); 5-OH (5);
3-OCH3 (6); 4-OCH3 (7); 5-OCH3 (8);
3-Cl (9); 5-Cl (10); 3,5-Cl (11); 5-NO2 (12)
Fig. 1. Structures of aroylhydrazones 1–13.
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As a part of our investigations on aromatic hydrazones derived from nicotinic acid 
hydrazide (10), a group of 13 derivatives (Fig. 1) was studied for antimicrobial activity in 
the present work. Our research was focused on antibacterial, antifungal and antibiofilm 
studies in vitro. 
EXPERIMENTAL
Chemicals
Chemicals used in this study, such as acetic acid glacial (Panreac, Spain), dimethyl 
sulfoxide pure (Lach-Ner, Czech Republic), methanol (Merck KgaA, Germany), are com-
mercially available and were used without further purification, while aroylhydrazone de-
rivatives were synthesized by previously described procedures (11) and analyzed using 
standard analytical methods. Drugs used as positive controls were gentamicin sulphate 
and colistin purchased from Sigma-Aldrich, nystatin from PLIVA Hrvatska (Croatia), nor-
floxacin from Krka-Farma (Slovenia) and voriconazole from Pfizer (USA).
Microorganisms and media
Several microorganisms, standard laboratory strains from the American Type Culture 
Collection (ATCC) and resistant clinical strains, were obtained from stock cultures of the 
Collection of Microorganisms (MFBF), Department of Microbiology, Faculty of Pharmacy 
and Biochemistry, University of Zagreb, Croatia. Experiments included Staphylococcus au-
reus ATCC 6538 (methilicin susceptible strain), methicillin resistant S. aureus MFBF 10679 
(MRSA), Escherichia coli ATCC 10536, extended-spectrum beta-lactamase-positive E. coli 
(ESBL+ E. coli) MFBF 12794, Candida albicans ATCC 10231 (fluconasole-susceptible), flucona-
sole-resistant C. albicans MFBF 11103 (CaFLR+), and Aspergillus brasiliensis ATCC 16404. Mi-
crobiological media Mueller-Hinton broth, Mueller-Hinton+2 % glucose (m/V) broth and 
RPMI 1640+2 % (m/V) glucose broth were purchased from Merck (Germany).
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) were measured by the serial two-fold mi-
crodilution broth assay in Mueller-Hinton broth for bacterial strains, and RPMI with 2 % 
of glucose broth for fungi according to the recommendations of EUCAST protocols (12, 13).
Compounds 1–13 were first dissolved in DMSO/water (1:1, V/V), followed by dilution 
with sterile physiological saline to a stock concentration of 800 µg mL–1. The solvent mix-
ture was tested as a negative control in all assays.
Inoculum suspensions of bacteria and fungi were prepared from fresh cultures of 
microbial strains cultured on the surface of tryptic-soy agar for 18 h at 35 °C for bacterial 
species, and on Sabouraud 2 % (m/V) glucose agar for 48 h at 35 °C for yeast and fungi. 
Inocula were prepared with physiological saline and cell density was adjusted to 0.5 Mc-
Farland units using a nephelometer (Kisker, Germany). Working microbial suspensions 
were prepared as 1:10 dilutions in Mueller-Hinton broth for bacteria, and RPMI-2 % glu-
cose broth for yeast and fungi. Final bacterial suspensions contained approximately 107 
CFU mL–1 and the yeast/mold suspensions 5 ´  106 CFU mL–1. Serial two-fold microdilution 
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testing was performed for all compounds in concentrations from 200 to 0.1 µg mL–1. After 
inoculation and aerobic incubation for 18 h at 35 °C in the dark, MICs of bacterial strains 
were determined by adding the redox-indicator 2,3,5-triphenyl-2H-tetrazolium chloride 
[TTC, 1.0 % (m/V), in sterile physiological saline]. After 3 hours of incubation at 35 °C in the 
dark, 0.04 mol L–1 HCl in isopropanol was added to all wells and absorbance was recorded 
at 540 nm using a microtiter plate reader (Labsystems iEMS Reader MF, Finland). MIC was 
defined as the lowest concentration of investigated compounds that inhibited 90 % of the 
growth compared to the negative control; values for 50 % growth inhibition are shown as 
well. MICs for C. albicans strains were obtained by determing absorbance at 540 nm using 
the above mentioned microtiter plate reader. MIC values for mold A. brasiliensis ATCC 
16404 were determined visually after 48 h of incubation, aerobically at 35 °C in the dark. 
MICs were calculated using the Gompertz non-linear regression model, evaluating the % 
microbial viability vs. logconc (GraphPad Prism version 6.00 for Windows, GraphPad Soft-
ware, La Jolla California USA, www.graphpad.com) to get the final IC90 and IC50 values 
expressed in mg mL–1. All tests were performed in triplicate and results are expressed as 
the mean value. Minimal inhibitory concentrations are shown in Table I.
Determination of anti-biofilm activity
Compounds that showed antimicrobial activity against the tested clinical microbial 
strains MRSA MFBF 10679, ESBL+ E. coli MFBF 12794 and CaFLR+ MFBF 11103 were investi-
gated for anti-biofilm activity using the crystal violet assay according to Vlainić et al. (14) 
with slight modifications. The effect on biofilm formation was evaluated by determining 
the minimum biofilm formation inhibition concentration (MBFIC). Inoculum suspensions 
of fresh cultures of microbial strains were prepared with sterile physiological saline and 
cell density was adjusted to 0.5 McFarland units using a nephelometer (Kisker). Working 
suspensions of bacteria and yeast used in experiments were prepared as 1:10 dilutions in 
RPMI 1640+2 % (m/V) glucose broth for yeast, and Mueller-Hinton+2 % glucose (m/V) broth 
for bacteria. Final bacterial suspensions contained 107 CFU mL–1 and yeast suspensions 5 
´ 106 CFU mL–1. Experiments were performed in sterile 96-well flat-bottom plastic tissue 
plates (TPP, Switzerland). Investigated compounds were tested in the concentration range 
from 500 to 3.91 µg mL–1. Untreated controls contained inoculum in broth, and standard 
antimicrobial drugs were used for positive controls – gentamicin sulphate (stock concen-
tration used for ESBL+ E. coli MFBF 12794 was 1 mg mL–1, while stock concentration for 
MRSA MFBF 10679 was 600 µg mL–1), norfloxacin (stock concentration of 1 mg mL–1) for 
bacteria, nystatin and voriconazole (stock concentration of 400 µg mL–1 each) for fungi. 
Only broth was used for negative controls. After a 24-h incubation period for bacteria and 
48 h of incubation for yeast (37 °C, aerobic, in the dark), wells were aspirated and washed 
four times with 250 µL of PBS and shaken vigorously. Adherent microbial cells were treat-
ed with methanol for 20 min and left to dry overnight. The formed biofilm was stained 
with crystal violet (0.5 %, m/V, in methanol) for 10 min. Residual crystal violet was aspi-
rated and plates were rinsed with tap water and left to dry overnight. Adherent biofilm 
was resolubilized with glacial acetic acid. Results were obtained by measuring absorbance 
at 540 nm using a microtiter plate reader (Labsystems iEMS Reader MF). The MBFIC50 and 
MBFIC90 values represent the lowest compound dilutions at which microbial growth dur-
ing biofilm formation was inhibited by 50 and 90 %, resp., compared to the untreated 
control (inoculum with broth). MBFICs were calculated from linear regression of the log 
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of concentration of compounds vs. % reduction, using the GraphPad Prism version 6.00 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. All tests 
were performed in triplicate and the results are expressed as the mean value.
RESULTS AND DISCUSSION
All the compounds 1–13 were screened for their in vitro antibacterial activity against 
S. aureus (Gram-positive) and E. coli (Gram-negative) strains, C. albicans (yeast) and A. 
brasiliensis (filamentous fungus).
Susceptibility of the tested microbial species to aroylhydrazone compounds showed 
species-dependent and compound-dependent activity. Pronounced activities were detected 
for compounds 2, 6, 7, 8, 10, 11, 12 and 13. Compounds 2, 6, 7, 11 and 12 showed good 
 activity against multi-resistant clinical strains MRSA, ESBL+ E. coli and C. a.FLR+, still lower 
than that of reference drugs. The same applies to compounds 11 and 12, which were highly 
active against S. aureus ATCC 6538 (both 11 and 12), C. albicans ATCC 10231 (11) and E. coli 
ATCC 10536 (11) but still not as active as the standard drugs. Compound 6 showed activity 
against the S. aureus ATCC 6538 strain with IC90 range 6.0 ´ 10–2–0.48 µmol mL–1, while 
compounds 11 and 12 showed even better antibacterial activity against S. aureus, with the 
lowest MIC value of 5.16 ´ 10–3 µmol mL–1 (MIC range 5.16 ´ 10–3–0.2 µmol mL–1 for com-
pound 11) as well as against the E. coli ATCC 10536 strain (IC90 range 0.17–0.37 µmol mL–1). 
Compound 2 showed antibacterial activity against E. coli with the MIC range 0.18–0.23 
µmol mL–1, whereas compound 10 showed enhanced activity against E. coli with the MIC 
range 0.11–0.20 µmol mL–1. In all of these cases, MIC values were markedly higher than for 
standard drugs. Good activity against both investigated C. albicans strains was shown by 
compound 11. The lowest MIC value of 4.0 ´  10–2 µmol mL–1 against C. albicans ATCC 10231 
was fairly comparable with the lowest MIC value of nystatin of 1.7 ´ 10–2 µmol mL–1. Com-
pound 7 showed somewhat lower activity against both C. albicans strains with higher MIC 
values (IC90 range 0.18–0.10 µmol mL–1). Only compound 12 showed good activity against 
the MRSA strain, but still markedly lower than gentamicin sulphate. Compounds 2, 6 and 
12 showed activity against ESBL+ E. coli MFBF 12794, with the lowest MIC in the case of 
compound 12 (IC50 0.16 µmol mL–1); however, still markedly higher than that of colistin 
(IC50 4.63 ´ 10–5 µmol mL–1).
None of the tested compounds showed a wide spectrum of antibacterial activity 
against multi-resistant clinical strains and none of the compounds showed activity against 
A. brasiliensis in the concentration range tested.
Antibacterial tests performed in this study showed that compounds 10 and 11, bear-
ing one and two chloro atoms, resp., as well as compound 12 with a nitro group, showed 
good inhibition of bacterial growth whereas the compounds without an electron with-
drawing group (chloro- and nitro-) showed weak antimicrobial activity. This may be due 
to the fact that electron withdrawing substituents (chloro-, nitro-) increase the lipophilic-
ity of the compounds, which leads to higher partitioning of such compounds into the li-
pophilic phase of a microbial membrane. This causes higher local concentration of the 
compound near a biological target site (1). Furthermore, hydrazones with a strong elec-
tron withdrawing substituent (fluorine) showed high bioactivity and were commonly 
used in medicine to improve metabolic stability, bioavailability and protein ligand inter-
actions (15).
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According to the experimental results, none of the compounds under investigation 
showed anti-biofilm activity of C. a.FLR+ at the tested concentrations. As shown in Table II, 
anti-biofilm activity of compounds 2 and 12 was detected in the case of MRSA and EBSL 
+ E. coli. Compound 2 showed good activity only against the formation of biofilm formed 
by MRSA, while compound 12 showed good activity only against the formation of biofilm 
formed by EBSL + E. coli. In the case of compound 2 against MRSA biofilm formation, 
MBFIC values (1.5 ´ 10–2 µmol mL–1–2.0 ´ 10–2 µmol mL–1) were comparable to those of 
gentamicin sulphate (1.2 ´ 10–2 µmol mL–1–1.4 ´ 10–2 µmol mL–1), whereas in the case of 
compound 12 and  EBSL+ E. coli even more favourable activity versus gentamicin was re-
corded. Results reveal that the type of substituent in the molecule that determines hydro-
phobicity/hydrophilicity of the hydrazone could be affecting quorum sensing systems 
(QS) involved in anti-biofilm activity and, therefore, in future, further investigation of this 
issue should be performed.
Compounds containing electron withdrawing groups generally exert better antimi-
crobial activity against Gram-negative bacteria. These findings can be explained by the 
differences between Gram-negative and Gram-positive bacteria. Gram-negative bacteria 
are surrounded by a thin peptidoglycan cell wall, which itself is surrounded by an outer 
membrane containing lipopolysaccharide. Gram-positive bacteria lack an outer membrane 
but are surrounded by layers of peptidoglycan many times thicker than those found in 
Gram-negative bacteria. Nitro group is a strong electron-withdrawing group, situated in 
para position to a hydroxyl group in compound 12, which leads to increased lipophilicity. 
Increased lipophilicity promotes entrance of substances into the cell membrane and causes 
structural defects leading to cell death. As already mentioned, compound 12 (nitro substi-
tuted) showed high activity against the formation of a biofilm formed by the Gram-nega-
tive bacterium (EBSL+ E. coli).
CONCLUSIONS
All the title compounds were screened for their in vitro antimicrobial activity against 
S. aureus (Gram-positive bacterium), E. coli (Gram-negative bacterium), C. albicans and A. 
Table II. MBFIC50 and MBFIC90 values of in vitro antimicrobially active aroylhydrazone derivatives
Compound
MBFIC
(µmol mL–1)
Microorganism
MRSA MFBF 10679 ESBL+ E. coli MFBF 12794
2
MBFIC50 1.54 ´ 10–2 > 2.07 ´ 10–2
MBFIC90 2.03 ´ 10–2 > 2.07 ´ 10–2
12
MBFIC50 > 1.75 ´ 10–2 1.32 ´ 10–2
MBFIC90 > 1.75 ´ 10–2 1.34 ´ 10–2
Gentamicin 
sulphate
MBFIC50 1.17 ´ 10–2 > 0.17
MBFIC90 1.36 ´ 10–2 > 0.17
Norfloxacin
MBFIC50 > 0.78 > 0.78
MBFIC90 > 0.78 > 0.78
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brasiliensis. The activity was detected for the compounds N’-(2-hydroxy-phenylmethylidene)-
3-pyridinecarbohydrazide (2), N’-(2-hydroxy-3-methoxyphenylmethylidene)-3-pyridine-
carbohydrazide (6), N’-(2-hydroxy-5-methoxyphenylmethylidene)-3-pyridinecarbohydra-
zide (7), N’-(2-hydroxy-5-methoxyphenylmethylidene)-3-pyridinecarbohydrazide (8), 
N’-(5-chloro-2-hydroxyphenylmethylidene)-3-pyridinecarbohydrazide (10), N’-(3,5-chlo-
ro-2-hydroxyphenylmethylidene)-3-pyridinecarbohydrazide (11), and N’-(2-hydroxy-
5-nitrophenylmethylidene)-3-pyridinecarbohydrazide (12). Compounds 11 and 12 showed 
antibacterial activity against S. aureus and E. coli strains, while compounds 6 and 8 showed 
activity only against S. aureus. Compounds 2 and 10 were active against E. coli. Experimen-
tal results reveal that compounds 6, 8, 11 and 12 exhibited strong antibacterial activity 
against S. aureus. As the obtained results show, only compound 12 showed strong activity 
against MRSA. Furthermore, only compound 11 showed activity against C. albicans ATCC 
10231 comparable to the activity of nystatin. 
Compounds 2, 6, 10, 11 and 12, which showed good antimicrobial activity, were also 
investigated on multi-resistant clinical strains MRSA, ESBL+ E. coli and C. a.FLR+. Experi-
mental results showed that only compounds 2 and 12 showed good activity against biofilm 
formation. Compound 2 showed good activity against formation of the biofilm formed by 
MRSA, while compound 12 showed only good activity against formation of the biofilm 
formed by EBSL + E. coli. In the case of compound 2 against MRSA biofilm formation, 
MBFIC values were comparable to those of gentamicin sulphate, whereas in the case of 
compound 12 and EBSL+ E. coli even more favourable activity compared to gentamicin was 
observed.
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